come well-ahead expect
strong setup
revenu our/street core growth
organ basi ex-abaxi fx headwind compar
core growth estim organ exclud abaxi beat broad-bas
led companion anim strength despit tough comp strong livestock
result ou driven top-line volum mix gm yoy
adj opm despit initi dilut abaxi acquisit
adj ep ahead street first look detail
driver continu perform particularli dermatolog
segment/geographi result solidli in-lin just-ahead
expect robust perform dermatolog portfolio yoy
drive beat steadi out-performance product even rel
aggress estim reaffirm confid continu runway
target dermatolog seem bag sale
see sale potenti approach particularli
addit indic approv cytopoint allerg dermat runway
intern expans strong return dtc campaign us
abaxi updat posit earli result accret
initi abaxi result broadli in-lin expect vs
estim partial quarter face inventori draw-down distributor
normal growth double-digit integr proceed well
see long runway invest busi drive intern expans
higher util custom acquisit becom mildli accret
minor tweak estim reiter buy po
adjust model larg fx see
revenu off-set stronger oper result ep estim move
reiter buy rate rais
po po price-to-earnings remain anim health focu stock
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
zoeti global leader discoveri
develop manufactur
commerci anim health medicin
vaccin product companion
anim market well-diversifi portfolio
product line span eight core
speci five therapeut categori directli
market countri industri
believ zoeti benefit rise
demand companion product anim
health product particularli emerg market
new product product line extens
expand ancillari servic offer greater
oper work capit effici
opportunist invest acquisit and/or
partnership supplement growth
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
po base ep previous estim back
dcf assum wacc termin growth rate modest
premium compani broader blend peer group in-lin current
multipl justifi given upsid new product launch increment
capit deploy margin expans opportun defens natur
busi
downsid risk price object competit select market weaker demand
anim health product regulatori issu macroeconom condit currenc risk
headwind relat regul antibiot use anim feed addit
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
